BENESTENT

BENESTENT

A trial comparing elective Palmaz-Schatz Cordis stenting to balloon angioplasty in patients with stable angina and a single coronary lesion.
 
Conclusions
Ultrasound guidance resulted in larger acute stent dimensions without increased complications; revascularisation was decreased with ultrasound (8%) vs angiographic guidance (12%).
Mentioned in ?
References in periodicals archive ?
In the BENESTENT study, 20% of patients receiving a stent had major adverse clinical events within six months of stent placement, while 30% of patients not receiving a stent following angioplasty had major adverse clinical events within the same time period.
Serruys compared the DEBATE study data to the results of the BENESTENT study published in The New England Journal of Medicine in August 1994, for which he was also the principal investigator.
Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials.
These studies included STRESS (utilized original PALMAZ-SCHATZ Stent), BENESTENT (European PALMAZ-SCHATZ trial), BENESTENT II (heparin-coated PALMAZ-SCHATZ Stent), STARS (Stent Antithrombotic Regimen Study - stent including anticoagulation with aspirin, aspirin/ticlopidine, or aspirin/warfarin) and two Palmaz-Schatz CROWN Stent registries, including stents of 15 mm and 30 mm in length, respectively.
a 18% rate in the STARS clinical study, a 15% rate in the STRESS study and rates of 7% and 13% in the BENESTENT I and II clinical studies, respectively.
Serruys, who played a key role in bringing coronary stents into clinical practice as the principle investigator of the famous BENESTENT trials six years ago, is very familiar with brachytherapy and feels that IST offers some distinct advantages.
The BENESTENT I trial was funded by a grant from Cordis, a Johnson & Johnson company.
These findings at the five-year time-point of the BENESTENT I trial are exceptionally gratifying," said Patrick W.